Biologic therapy with anti-TNFa in spondyloarthritides and other autoimmune diseases

Abstract

Objective: To evaluate the efficacy of the anti-TNFa (Tumor Necrosis Factor alpha) drugs in a variety of pathologic conditions such as psoriatic arthritis, undifferentiated entheso-arthritides, chronic inflammatory bowel diseases, adult onset Still’s disease, Behcet disease. Methods: Review of all published studies evaluating the efficacy of these drugs (mainly infliximab and etanercept, adalimumab to a lesser degree) on the above diseases. Results: Results are reported for each pathologic condition. Both drugs showed to be very efficacious in all the above conditions, except Crohn disease where etanercept does not seem adequate. Conclusions: Both drugs work extremely well, even though comparison between infliximab and etanercept efficacy cannot be performed, due to the lack of a direct comparison.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Info
Issue
Section
Articles
Statistics
  • Abstract views: 381

  • PDF: 734
How to Cite
Lapadula, G. (1). Biologic therapy with anti-TNFa in spondyloarthritides and other autoimmune diseases. Reumatismo, 57(4s), 22-29. https://doi.org/10.4081/reumatismo.2005.4s.22

Most read articles by the same author(s)

1 2 > >>